All lobbying filings

TODD STRATEGY GROUP

Lobbying for NOVARTIS, INC. · â€‹Multinational biopharmaceutical company.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Jul 20, 2025

Official filing document

Bills named in this filing 5

HR 1672
Maintaining Investments in New Innovation Act
S 832
EPIC Act of 2025
HR 5376
Impacts and Outcomes for Health Career Training Act
S 3131
ORPHAN Cures Act
HR 5539
ORPHAN Cures Act

Lobbying activity 3

Medicare/Medicaid

Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.

Tariff (miscellaneous tariff bills)

Traffic policies.

Health Issues

Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.